Douglas Pharmaceuticals diversifies, shoots for near quarter-billion dollar turnover

Douglas Pharmaceuticals diversifies, shoots for near quarter-billion dollar turnover
By Fiona Rotherham Feb. 13 (BusinessDesk) - Douglas Pharmaceuticals, New Zealand’s largest developer and manufacturer of generic pharmaceuticals, is targeting annual revenues of $244 million by 2020 from $145 million today as it diversifies and seeks higher risk, higher reward opportunities in novel drug development. The traditionally media-shy Auckland-based company told BusinessDesk that growing exports, particularly into the US, Asia, and Middle East, was also critical to meeting the target, set in mid-2013. Douglas Pharmaceuticals...